ASPIRIN HELPS IN CSR (CENTRAL SEROUS RETINOPATHY)

Low-dose aspirin as treatment for central serous chorioretinopathy

Central Serous Retinopathy (CSR) causes blurriness of central vision for about a 3 month period of time. It often occurs spontaneously in individuals with type-A personalities. It is caused by leakage and subsequent swelling in the part of the retina that affects central vision. To date there have been no significant treatments except to monitor and await spontaneous resolution.

This study evaluates the effectiveness of aspirin for the treatment of CSR. Patients with CSR were treated with aspirin 100 mg per day orally for 1 month followed by 100 mg on alternate days for 5 months.

Results: Mean visual acuity in the group treated with aspirin started to improve after the first week of therapy and continued to improve throughout the following 3 months. Visual recovery was slower in the untreated control group than in the treated group and achieved better visual acuity between the first and third month from the onset of the disease. There were no adverse events related to the administration of aspirin.

Conclusion: The results indicate that treatment with low-dose aspirin may result in more rapid visual rehabilitation with fewer recurrences in patient with CSR compared with untreated controls.